Previous Page  40 / 55 Next Page
Information
Show Menu
Previous Page 40 / 55 Next Page
Page Background

before August 8, 2016 will be able to

stay on store shelves for the two-year pe-

riod manufacturers have to file an FDA

approval application, after which it will

be up to FDA whether the products can

continue to be sold. Products not on the

market by the August 8, 2016 deadline

will not be able to enter the market until

they have been approved by FDA. How-

ever, all of those facts could still change

depending on the success of a number

of efforts under way by industry asso-

ciations, noted Schaevitz, who explained

that IPCPR has teamed up with partner

associations Cigar Rights of America

(CRA) and Cigar Association of Amer-

ica (CAA) on a lawsuit challenging the

predicate date and the decision to use the

same substantial equivalence process for

cigars and pipe tobacco.

The suit asks for a declaratory injunc-

tion to “vacate, set aside and enjoin the

enforcement of the final rule” because it

violates numerous federal statutes as well

as the federal rulemaking process. “There

are nine separate counts, including chal-

lenging the predicate date that forces the

cigar industry to look back nine years

to find grandfathered products,” he ex-

plained. “Cigarettes and smokeless prod-

ucts [were regulated] in 2009, so [they]

only had to look back two years.”

In addition to the predicate date, the

industry is fighting on other fronts.

“FDA has taken the view that any

change to a cigar blend or pipe tobac-

co makes it a new product,” explained

Dave Clissold of Hyman Phelps, who

said that FDA might ultimately make

allowances for some natural variations

in cigars from year to year. “We argued

to FDA very strongly years ago that ci-

gars are completely different siblings in

that there are natural variations due to

weather conditions and availability of

tobacco. FDA accepted that argument

and said natural variations will not nec-

essarily be [considered] a new product.

Exactly what constitutes a natural varia-

tion is one of the things we will have to

work out with FDA.”

The lawsuit also challenges the health

warning requirements in the new rule,

EVENT HIGHLIGHT

74

TOBACCO BUSINESS INTERNATIONAL

SEPTEMBER/OCTOBER 2016